ECSP21040300A - Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica - Google Patents
Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémicaInfo
- Publication number
- ECSP21040300A ECSP21040300A ECSENADI202140300A ECDI202140300A ECSP21040300A EC SP21040300 A ECSP21040300 A EC SP21040300A EC SENADI202140300 A ECSENADI202140300 A EC SENADI202140300A EC DI202140300 A ECDI202140300 A EC DI202140300A EC SP21040300 A ECSP21040300 A EC SP21040300A
- Authority
- EC
- Ecuador
- Prior art keywords
- oxopyrrolidin
- butanamide
- proportion
- racemic
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 title 2
- 230000002195 synergetic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical group C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- HPHUVLMMVZITSG-UHFFFAOYSA-N Etiracetam Chemical compound CCC(C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-UHFFFAOYSA-N 0.000 abstract 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención se refiere a una composición de los enantiómeros de 2-(2-oxopirrolidin-1-il)butanamida y solvatos o co-cristales farmacéuticamente aceptables de la misma en una cierta proporción, una composición farmacéutica que comprende dicha composición, su uso como un medicamento y el uso de las composiciones o composiciones farmacéuticas inventivas en el tratamiento y/o prevención de una enfermedad o trastorno seleccionado generalmente y preferiblemente de trastornos relacionados con las convulsiones, neuropatía sensorial periférica, preferiblemente dolor neuropático periférico; convulsiones; depresión; o deterioro cognitivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18210106 | 2018-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21040300A true ECSP21040300A (es) | 2021-07-30 |
Family
ID=64604549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202140300A ECSP21040300A (es) | 2018-12-04 | 2021-06-03 | Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220047548A1 (es) |
| EP (1) | EP3890833B1 (es) |
| JP (2) | JP2022510363A (es) |
| KR (1) | KR20210099567A (es) |
| CN (1) | CN113164767A (es) |
| AU (1) | AU2019391309A1 (es) |
| BR (1) | BR112021010739A2 (es) |
| CA (1) | CA3117350A1 (es) |
| CO (1) | CO2021007055A2 (es) |
| EA (1) | EA202191485A1 (es) |
| EC (1) | ECSP21040300A (es) |
| ES (1) | ES2953785T3 (es) |
| HU (1) | HUE062575T2 (es) |
| IL (1) | IL283441A (es) |
| JO (1) | JOP20210082A1 (es) |
| MX (1) | MX2021006243A (es) |
| PH (1) | PH12021551305A1 (es) |
| PL (1) | PL3890833T3 (es) |
| SG (1) | SG11202105863PA (es) |
| WO (1) | WO2020115093A1 (es) |
| ZA (1) | ZA202102701B (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412358D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| CA2488325C (en) * | 2004-11-22 | 2010-08-24 | Apotex Pharmachem Inc. | Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| CN101511786A (zh) * | 2006-07-25 | 2009-08-19 | Zach系统股份公司 | 制备左乙拉西坦的方法 |
| WO2009058261A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| EP2098526B1 (en) | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| EP2671858A1 (en) * | 2012-06-08 | 2013-12-11 | Université Catholique De Louvain | Process for chiral resolution of etiracetam |
| JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
-
2019
- 2019-12-04 JP JP2021531433A patent/JP2022510363A/ja active Pending
- 2019-12-04 EA EA202191485A patent/EA202191485A1/ru unknown
- 2019-12-04 PH PH1/2021/551305A patent/PH12021551305A1/en unknown
- 2019-12-04 CA CA3117350A patent/CA3117350A1/en active Pending
- 2019-12-04 US US17/299,928 patent/US20220047548A1/en not_active Abandoned
- 2019-12-04 HU HUE19813837A patent/HUE062575T2/hu unknown
- 2019-12-04 WO PCT/EP2019/083594 patent/WO2020115093A1/en not_active Ceased
- 2019-12-04 MX MX2021006243A patent/MX2021006243A/es unknown
- 2019-12-04 KR KR1020217016689A patent/KR20210099567A/ko not_active Ceased
- 2019-12-04 BR BR112021010739-8A patent/BR112021010739A2/pt unknown
- 2019-12-04 CN CN201980076384.6A patent/CN113164767A/zh active Pending
- 2019-12-04 JO JOP/2021/0082A patent/JOP20210082A1/ar unknown
- 2019-12-04 AU AU2019391309A patent/AU2019391309A1/en not_active Abandoned
- 2019-12-04 SG SG11202105863PA patent/SG11202105863PA/en unknown
- 2019-12-04 PL PL19813837.2T patent/PL3890833T3/pl unknown
- 2019-12-04 ES ES19813837T patent/ES2953785T3/es active Active
- 2019-12-04 EP EP19813837.2A patent/EP3890833B1/en active Active
-
2021
- 2021-04-22 ZA ZA2021/02701A patent/ZA202102701B/en unknown
- 2021-05-25 IL IL283441A patent/IL283441A/en unknown
- 2021-05-28 CO CONC2021/0007055A patent/CO2021007055A2/es unknown
- 2021-06-03 EC ECSENADI202140300A patent/ECSP21040300A/es unknown
-
2024
- 2024-10-11 JP JP2024178838A patent/JP2025020146A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA202191485A1 (ru) | 2021-08-30 |
| AU2019391309A1 (en) | 2021-05-20 |
| PH12021551305A1 (en) | 2022-05-16 |
| HUE062575T2 (hu) | 2023-11-28 |
| SG11202105863PA (en) | 2021-07-29 |
| JP2025020146A (ja) | 2025-02-12 |
| EP3890833B1 (en) | 2023-06-07 |
| ZA202102701B (en) | 2023-10-25 |
| JP2022510363A (ja) | 2022-01-26 |
| CN113164767A (zh) | 2021-07-23 |
| US20220047548A1 (en) | 2022-02-17 |
| CO2021007055A2 (es) | 2021-06-10 |
| MX2021006243A (es) | 2021-08-11 |
| ES2953785T3 (es) | 2023-11-16 |
| WO2020115093A1 (en) | 2020-06-11 |
| CA3117350A1 (en) | 2020-06-11 |
| KR20210099567A (ko) | 2021-08-12 |
| EP3890833A1 (en) | 2021-10-13 |
| BR112021010739A2 (pt) | 2021-08-24 |
| PL3890833T3 (pl) | 2023-09-18 |
| EP3890833C0 (en) | 2023-06-07 |
| JOP20210082A1 (ar) | 2023-01-30 |
| IL283441A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2025000288A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| ES3064032T3 (en) | Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies | |
| MX2022007155A (es) | Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos. | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| ECSP19085426A (es) | Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica | |
| MX390536B (es) | Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico. | |
| EP4008718C0 (en) | HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE | |
| MX2020004107A (es) | Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas. | |
| CO2021007055A2 (es) | Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica | |
| BR112021019779A2 (pt) | Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo | |
| EP3818981A4 (en) | SYNERGIC PHARMACEUTICAL COMPOSITION OF ACTIVE ENANTIOMER (S)-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN | |
| CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
| EA202000347A1 (ru) | ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР | |
| CO2020001881A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol | |
| GT199900083A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica. | |
| MX2022001023A (es) | Compuestos de aminotiolester y usos de los mismos. | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| ZA202311560B (en) | Immediate release fixed-dose combination of memantine and donepezil | |
| EA202191486A1 (ru) | СИНЕРГЕТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ R-2-(ЗАМЕЩЕННЫЙ СУЛЬФОНИЛ)ГЕКСАГИДРОПИРРОЛО[1,2-а]ПИРАЗИН-6(2H)ОНЫ И S-2-(ЗАМЕЩЕННЫЙ СУЛЬФОНИЛ)ГЕКСАГИДРОПИРРОЛО[1,2-а]ПИРАЗИН-6(2H)ОНЫ В НЕРАЦЕМИЧЕСКОМ СООТНОШЕНИИ | |
| CL2023000845A1 (es) | Una sal farmacéutica de un derivado de arilpirrol | |
| UA113233U (uk) | Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента |